Notice Concerning Filing of Form S-3 Registration Statement by Gyre Therapeutics
Filed with TSE · · 1 page · English
Summary by 6ix AI
This filing is related to Gyre's acquisition of Cullgen Inc. and involves shares issued to Cullgen stockholders as consideration for the acquisition. The filing does not aim to raise new capital and is not expected to materially impact GNI Group's consolidated financial results.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/notice-concerning-filing-of-form-s-3-registration-statement-by-gyre-therapeutics
Earlier from GNI
- GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
- Transformational Acquisition of Ayumi Pharmaceutical Holdings
- Financial Results Briefing for Q2 FY 2025 (on August 29, 2025)
- FY2023Q1 Earnings Call Transcript
- Amendment of “Q1 FY2023 Financial Results Corporate Presentation” document
Later from GNI
- Notice Regarding the Execution of a Loan Agreement Containing Financial Covenants
- Notice Concerning the Completion of the Acquisition of All Shares of AYUMI Pharmaceutical Holdings KK (Conversion into a Wholly-Owned Subsidiary)
- Consolidated Financial Results for Q2 FY2026 (IFRS)
- Q2 FY2026 Financial Results Corporate Presentation
- Notice Regarding Change in Major Shareholder
Follow GNI into a list and get an email when it puts out news.
Follow GNI